The Oklahoma Rheumatic Diseases Research Cores Center (ORDRCC) currently supports rheumatic disease research for 32 junior ORDRCC investigators (some from outside Oklahoma) and 16 senior Center Investigators. Through the Clinical Characterization and Biorepository, the ORDRCC provides clinically well characterized patient resources for adult and pediatric systemic lupus erythematosus (SLE), Sjogren's syndrome, rheumatoid arthritis, anti-phospholipid antibody syndrome and other diseases to our ORDRCC investigators. Additionally, ORDRCC investigators have access to cutting-edge technologies through our multi-disciplinary Phenotyping Core, which provides services in genetics, genomics, proteomics and immune phenotype/immune function assessment. The Administrative and Enrichment Core facilitates scientific advances and fosters multi-disciplinary interactions. Through implementation of these ORDRCC resources and activities, over the past funding cycle our rheumatic disease publications have doubled, our rheumatic disease publications including multiple ORDRCC investigators have tripled and rheumatic disease publications with other outside investigators have more than quadrupled. Along with this increase in collaborative, multidisciplinary rheumatic disease projects, our NIH funding has doubled, including several new multi-investigator grants which evolved out of ORDRCC interactions, including the Oklahoma Autoimmunity Center of Excellence and Center of Research Translational in Sjogren's. Eight of our junior investigators have graduated to Center status after receiving their initial independent NIH funding. Capitalizing on the scientific strengths of our ORDRCC Investigators, the overarching goals of our ORDRCC are to 1) integrate a multidisciplinary group of basic scientists and clinical investigators to study fundamental aspects of rheumatic disease, 2) fortify and expand this nucleus through directed recruitments, common educational forums, annual investigator meetings and collaborative scientific interactions, 3) offer access to critical, well-phenotyped clinical rheumatic disease collections, facilitating rheumatic disease research throughout the US, 4) implement access to centralized cutting-edge technologies to facilitate their rheumatic disease research and 5) provide the administrative, financial, and technical foundation to Oklahoma RDRCC investigators to accelerate their progress in understanding the etiology, pathogenesis, and management of rheumatic disease through multidisciplinary approaches.
The Oklahoma Rheumatic Disease Research Cores Center facilitates, supports and expands multidisciplinary rheumatic disease research through developing junior investigators, attracting new talent to rheumatic disease research, participating in diverse Enrichment activities, supporting pilot projects, providing well-phenotyped samples to ORDRCC investigators for their individual studies and identifying, developing and applying new methodologies and technologies to facilitate rheumatic disease discoveries.
|Ratliff, Michelle L; Ward, Julie M; Merrill, Joan T et al. (2015) Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol 194:940-9|
|Freedman, Barry I; Langefeld, Carl D; Andringa, Kelly K et al. (2014) End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66:390-6|
|Ward, Julie M; Rose, Kira; Montgomery, Courtney et al. (2014) Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A. Arthritis Rheumatol 66:3404-12|
|Dozmorov, Mikhail G; Wren, Jonathan D; Alarcon-Riquelme, Marta E (2014) Epigenomic elements enriched in the promoters of autoimmunity susceptibility genes. Epigenetics 9:276-85|
|Ritterhouse, Lauren L; Lu, Rufei; Shah, Hemangi B et al. (2014) Vitamin d deficiency in a multiethnic healthy control cohort and altered immune response in vitamin D deficient European-American healthy controls. PLoS One 9:e94500|
|Young, K A; Terrell, D R; Guthridge, J M et al. (2014) Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. Lupus 23:360-9|
|Guthridge, Joel M; Lu, Rufei; Sun, Harry et al. (2014) Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am J Hum Genet 94:586-98|
|Munroe, Melissa E; Vista, Evan S; Guthridge, Joel M et al. (2014) Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 66:1888-99|
|James, Judith A (2014) Clinical perspectives on lupus genetics: advances and opportunities. Rheum Dis Clin North Am 40:413-32, vii|
|Kim-Howard, Xana; Sun, Celi; Molineros, Julio E et al. (2014) Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Hum Mol Genet 23:1656-68|
Showing the most recent 10 out of 91 publications